Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 53 |
| Active Pipeline (Recruiting Now) | 41 (28) |
| Completed vs Stopped Early | 8 / 4 (7.5%) |
| Median Closed Actual Enrollment | 73 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Cancer Care Specialists of Illinois - Decatur | Decatur, IL | 34 |
| Decatur Memorial Hospital | Decatur, IL | 32 |
| University of Oklahoma Health Sciences Center | Oklahoma City, OK | 32 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05642611 | Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy | Phase III | RECRUITING |
| NCT03851445 | Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | Phase II/III | RECRUITING |
| NCT07393555 | Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded | Phase II | RECRUITING |
| NCT06116682 | Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) | Phase II | RECRUITING |
| NCT06616584 | Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment W | Phase II/III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the SWOG Cancer Research Network Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.